Gossamer Bio Inc. (NASDAQ:GOSS) finished Thursday with an addition of $0.21 to close at $2.23, an upside of 10.40 percent. An average of 5,810,240 shares of common stock have been traded in the last five days. There was a gain of $0.28 in the past week, and it reached a new high 14 times over the past 12 months. The last 20 days have seen an average of 11,698,220 shares traded, while the 50-day average volume stands at 5,641,908.
GOSS stock has decreased by -73.95% in the last month. The company shares reached their 1-month lowest point of $1.57 on 12/23/22. With the stock rallying to its 52-week high on 08/25/22, shares of the company touched a low of $1.57 and a high of $15.19 in 52 weeks. It has reached a new high 13 times so far this year and lost -80.28% or -$9.08 in price. In spite of this, the price is down -85.32% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
GOSS stock investors should be aware that Gossamer Bio Inc. (GOSS) stock had its last reported insider trading activity 67 days ago on Oct 24. In this transaction, the insider spent $57,431. Chief Scientific Officer, Carter Laura, disposed of 4,876 shares at a price of $12.07 on Oct 24. The insider now owns more than $58,868 worth of shares. Prior to that, Chief Medical Officer Aranda Richard went on to Sale 4,757 shares at $12.07 each on Oct 24. An amount of $57,431 was transacted.
Gossamer Bio Inc. (GOSS) stock’s beta is 1.16. Other valuation ratios to consider include the price-to-book (PB) ratio at 3.60.
The quick ratio of Gossamer Bio Inc. for the three months ended June 29 was 5.90, and the current ratio was 5.90, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 3.73 and a total debt to equity ratio of 3.93 for the quarter ending June 29. Its gross profit as reported stood at $19.44 million compared to revenue of $216.12 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Gossamer Bio Inc.’s return on assets was -76.10%.
For the three-month period that ended June 29, Gossamer Bio Inc. had $150.91 million in cash and short-term investments compared to $14.83 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$59.36 million in the quarter, while revenues of -$56.47 million were shrunk -1.5%. The analyst consensus anticipated Gossamer Bio Inc.’s latest quarter earnings to come in at -$0.7 per share, but it turned out to be -$0.74, a -5.70% surprise. For the quarter, EBITDA amounted to -$55.02 million. Shareholders own equity worth $94.48 million.
From a technical analysis perspective, let’s take a brief look at Gossamer Bio Inc. (GOSS) price momentum. RSI 9-day as of the close on 29 December was 35.06%, suggesting the stock is Neutral, with historical volatility in this time frame at 246.04%.
As of today, GOSS’s price is $1.93 +14.36% or $0.28 from its 5-day moving average. GOSS is currently trading -73.95% lower than its 20-day SMA and -82.87% lower than its 100-day SMA. However, the stock’s current price level is -82.16% below the SMA50 and -73.58% below the SMA200.
The stochastic %K and %D were 31.40% and 22.71%, respectively, and the average true range (ATR) was 0.51. With the 14-day stochastic at 47.83% and the average true range at 0.59, the RSI (14) stands at 29.61%. The stock has reached -0.05 on the 9-day MACD Oscillator while the 14-day reading was at -0.12.
SMBC Nikko downgraded Gossamer Bio Inc. (NASDAQ: GOSS) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as an Outperform. The consensus rating for Gossamer Bio Inc. (GOSS) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell GOSS, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 9 others rate it as a “buy”.
What is GOSS’s price target for the next 12 months?
Analysts predict a range of price targets between $2.00 and $15.00, with a median target of $7.00. Taking a look at these predictions, the average price target given by analysts for Gossamer Bio Inc. (GOSS) stock is $7.42.